跳至主要内容
临床试验/EUCTR2017-000519-18-FR
EUCTR2017-000519-18-FR进行中(未招募)1 期

PIMOC : Personalized targeted therapies in inflammatory complex multi organ disease - PIMOC

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)0 个研究点目标入组 32 人开始时间: 2018年9月25日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • -Patients (men or women) aged 18 years old and over
  • -Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. Skin involvement is mandatory in order to be able to compare involved and non involved tissue
  • -Signed informed consent
  • The disease should be considered as non-classified despite classical and adapted investigations and evaluation through expert committee meeting.
  • The disease alters significantly quality of life using SF36 assessment : score less than 30.
  • The disease has been resistant to at least two prior lines of treatment.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 19
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 13

排除标准

  • -Patients presenting disease which is not featured by lesional and healthy skin areas, easy to biopsy
  • -Patients refusing biopsies
  • -Pregnancy
  • -Women of child-bearing potential unable to receive highly efficient contraception such as combined oral contraceptives, intra-uterine disposals, hormonal implants or the use of male condoms recommended in case of unstable or irregular partner or as a replacement method for transient unacessebility to hormonal method
  • -Breastfeeding
  • -Patients presenting disease needing urgent therapeutic measures
  • -Patients without health insurance or social security
  • -Patients under legal protection
  • -Participation in another interventional trial
  • -Patients unable to respect the wash out delay of previously taken medications before inclusion time :
  • *Hydroxychloroquine (wash out period = 30 days)
  • *Chloroquine (wash out period = 7 days)
  • *Colchicine (wash out period = 7 days)
  • *Methotrexate (wash out period = 7 days)
  • *Ciclosporine (wash out period = 14 days)
  • *Azathioprine (wash out period = 14 days)
  • *Mycophenolate mofetil (wash out period = 14 days)
  • *Disulone (wash out period = 7 days)
  • *Corticosteroids (=prednisone, prednisolone, dexamethasone, methylprednisolone) (wash out period = 7 days)
  • -Patients with contra-indications to treatments: Severe or active infections including tuberculosis
  • Importantly, in this study, the treatment will be selected by a committee depending on three criteria (cf Design of the trial: Interpretation of the data) including contra indications of the patients to the drugs. Therefore, contra indicated medications cannot be selected by the committee in view of protocol participation.

研究者

相似试验